Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
New England Journal of Medicine2006Vol. 355(7), pp. 653–665
Citations Over TimeTop 1% of 2006 papers
Vance G. Fowler, Helen W. Boucher, G. Ralph Corey, Elías Abrutyn, Adolf W. Karchmer, Mark E. Rupp, Donald P. Levine, Henry F. Chambers, Francis P. Tally, Gloria Vigliani, Christopher H. Cabell, Arthur S. Link, Ignace Demeyer, Scott G. Filler, Marcus Zervos, Paul Cook, Julie Parsonnet, Jack Bernstein, Connie Price, Graeme N. Forrest, Gerd Fätkenheuer, Marcelo Gareca, Susan J. Rehm, H.-R. Brodt, Alan D. Tice, Sara E. Cosgrove
Abstract
Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis. (ClinicalTrials.gov number, NCT00093067 [ClinicalTrials.gov].).
Related Papers
- → Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin(2006)261 cited
- → Bacteremia due to Methicillin-Resistant Staphylococcus aureus(2016)43 cited
- → Bacteremia due to Methicillin-Resistant Staphylococcus aureus(2020)36 cited
- → A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin(2014)7 cited
- → Daptomycin for Infective Endocarditis(2013)